Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lamb

Showing results (651-660 of 674) with videos related to

Pageof 68
Sort By:
Nature Communications|March 17, 2022
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumabSimeng Lin, Nicholas A Kennedy, Aamir Saifuddin, et al.
Gut|January 19, 2026
Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn's and Colitis (PREdiCCt) prospective cohort studyNathan Constantine-Cooke, Beatriz Gros, Nikolas Plevris, et al.
Annals of the Rheumatic Diseases|September 13, 2015
Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroupsSimon Rothwell, Robert G Cooper, Ingrid E Lundberg, et al.
Gut|April 19, 2020
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemicNicholas A Kennedy, Gareth-Rhys Jones, Christopher A Lamb, et al.
Annals of the Rheumatic Diseases|May 30, 2019
Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroupsSimon Rothwell, Hector Chinoy, Janine A Lamb, et al.
Annals of the Rheumatic Diseases|January 15, 2018
Splicing variant of <i>WDFY4</i> augments MDA5 signalling and the risk of clinically amyopathic dermatomyositisYuta Kochi, Yoichiro Kamatani, Yuya Kondo, et al.
Annals of the Rheumatic Diseases|September 28, 2022
Low copy numbers of complement <i>C4</i> and <i>C4A</i> deficiency are risk factors for myositis, its subgroups and autoantibodiesDanlei Zhou, Emily H King, Simon Rothwell, et al.
Journal of Crohn'S & Colitis|August 20, 2025
Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-Centre UK studyChandni Radia, Yaa Danso, Susan Ritchie, et al.
The New England Journal of Medicine|June 10, 2026
Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel DiseaseNima Gharahdaghi, Pai-Jui Yeh, Lourdes Ceron-Gutierrez, et al.
BMJ Open|April 17, 2024
Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicineNicola J Wyatt, Hannah Watson, Carl A Anderson, et al.
Pageof 68

Showing results (651-660 of 674) with videos related to

Sort By:
Pageof 68
Nature Communications|March 17, 2022
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumabSimeng Lin, Nicholas A Kennedy, Aamir Saifuddin, et al.
Gut|January 19, 2026
Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn's and Colitis (PREdiCCt) prospective cohort studyNathan Constantine-Cooke, Beatriz Gros, Nikolas Plevris, et al.
Annals of the Rheumatic Diseases|September 13, 2015
Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroupsSimon Rothwell, Robert G Cooper, Ingrid E Lundberg, et al.
Gut|April 19, 2020
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemicNicholas A Kennedy, Gareth-Rhys Jones, Christopher A Lamb, et al.
Annals of the Rheumatic Diseases|May 30, 2019
Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroupsSimon Rothwell, Hector Chinoy, Janine A Lamb, et al.
Annals of the Rheumatic Diseases|January 15, 2018
Splicing variant of <i>WDFY4</i> augments MDA5 signalling and the risk of clinically amyopathic dermatomyositisYuta Kochi, Yoichiro Kamatani, Yuya Kondo, et al.
Annals of the Rheumatic Diseases|September 28, 2022
Low copy numbers of complement <i>C4</i> and <i>C4A</i> deficiency are risk factors for myositis, its subgroups and autoantibodiesDanlei Zhou, Emily H King, Simon Rothwell, et al.
Journal of Crohn'S & Colitis|August 20, 2025
Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-Centre UK studyChandni Radia, Yaa Danso, Susan Ritchie, et al.
The New England Journal of Medicine|June 10, 2026
Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel DiseaseNima Gharahdaghi, Pai-Jui Yeh, Lourdes Ceron-Gutierrez, et al.
BMJ Open|April 17, 2024
Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicineNicola J Wyatt, Hannah Watson, Carl A Anderson, et al.
Pageof 68